The US Food & Drug administration has granted orphan drug designation (ODD) to MeiraGTx’s adeno-associated virus (AAV)-mediated gene therapy product candidate for treatment of X-linked retinitis pigmentosa (XLRP).
Ten people with an inherited form of blindness will be fitted with retinal implants in a procedure funded by NHS England.
Eight patients with retinitis pigmentosa have received a stem cell injection in a 28-person safety study.
The Guardian reports blind animals have had their vision partially restored using a DNA editing technique that scientists say could in future be applied to a range of genetic diseases.
A patient with retinitis pigmentosa has reported that he could differentiate between light and dark for the first time in five years following the successful implant and activation of the IRIS II® bionic vision system, at Moorfields Eye Hospital NHS Foundation Trust in London.
Researchers have made a breakthrough in understanding what happens to the human brain after someone goes blind. The study out of the University of Pisa, Italy, found that the adult brain can actually learn to “see again” after a person went totally blind.
Targeting pathways with therapies could save sight in patients with many types of retinal disorders, including those for which there are no treatments, such as retinitis pigmentosa and advanced dry age-related macular degeneration.
Chronic inflammation of the retina may be the reason why therapies to treat retinal degeneration have failed to work in the long term, new research suggests.
Researchers have found a simple way to boost the efficiency of the ground-breaking gene-editing technology CRISPR-Cas9 by up to five times. CRISPR-Cas9 is a technique for knocking out genes in human cell lines to discover what the genes do but the efficiency with which it disables genes can vary immensely.
ReNeuron Group plc, a UK-based stem cell research company, has announced further key pre-clinical efficacy data with its human retinal progenitor cells (hRPCs). A Phase I/II clinical trial has recently commenced in the US to evaluate the safety, tolerability and preliminary efficacy of the hRPCs in patients with RP.